EBR Systems

EBR Systems is a pioneering private medical device company commercializing a novel, leadless solution for cardiac resynchronization therapy (CRT). Its flagship WiSE System uses ultrasound energy to power a miniaturized electrode implanted in the left ventricle, offering a physiological pacing approach for patients who cannot be treated effectively with traditional lead-based systems. The company has achieved regulatory approvals (CE Mark and FDA PMA) and is in the commercial stage, supported by recent Medicare reimbursement decisions. EBR's technology addresses a significant unmet need in the large and growing heart failure market, positioning it as a potential leader in next-generation CRT.

The WiSE Technology Platform enables leadless left ventricular endocardial pacing (LVEP) using ultrasound energy. It consists of an ultrasound transmitter integrated with a standard pacemaker/ICD and a miniaturized, leadless receiver-electrode implanted in the left ventricle that converts ultrasonic energy into electrical pacing pulses.

EBR competes in the CRT device market dominated by Medtronic, Abbott, and Boston Scientific, which offer traditional lead-based systems. Its WiSE System is first-to-market with a leadless LVEP solution, creating a unique niche. However, competitors are developing their own leadless pacing technologies (e.g., for the right ventricle), which could eventually be adapted for left ventricular use.